Aanwerving proef = ; Lopend onderzoek = ; Terminated trial = ; Gefinancierd door een IRDiRC-lid = ; Lid van een ERN =

Nationale klinische studie(s)

SPANJE

Madrid
ADDRESS: NOT PROVIDED - ES

EPIK-P2 - A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS) -ES

Institution: Information not provided - ES

Meer details

Multinationale klinische studie(s)

USA

Washington
ADDRESS: NOT PROVIDED - US

EPIK-P2: A Phase II Double-blind Study With an Upfront, 16-week Randomized, Placebo-controlled Period, to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

Institution: Information not provided - US

Meer details